Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
Andrea ChiricozziMichela OrtoncelliDonatella SchenaNiccolò GoriSilvia Mariel FerrucciGraziella BabinoMaddalena NapolitanoMaria Concetta FargnoliLuca StingeniMariateresa RossiMarco RomanelliRiccardo BalestriMichele PellegrinoAurora ParodiAlberto Maria BertoldiGiovanni PalazzoFlaminia AntonelliAnnalisa PitinoGiovanni TripepiGabriella FabbrociniAnna BalatoAngelo Valerio MarzanoGiampiero GirolomoniSimone RiberoKetty PerisPublished in: American journal of clinical dermatology (2023)
This study provides strong evidence of a sustained response obtained by upadacitinib in AD patients, who had failed to respond to conventional or biological systemic agents, through 48 weeks of observation. Upadacitinib was also demonstrated to be advantageous in terms of flexibility in dose reduction or escalation as upadacitinib dose was shaped on clinical needs that, in a real-world setting, might frequently change.